Chonluten: Scientific Profile

Publicado el 12 de julio de 2026 · Actualizado el 24 de agosto de 2026

Chonluten (CAS 75007-24-8) is a short tripeptide of sequence Glu-Asp-Gly (EDG), belonging to the family of peptide bioregulators described by the Khavinson group and studied in research models for its affinity toward bronchopulmonary tissue. It is proposed as a modulator of gene expression in respiratory cells, with a molecular weight of 319.27 g/mol. The available evidence is limited and comes mostly from preclinical studies by a single research group.

Chonluten is a synthetic tripeptide with the sequence Glu-Asp-Gly, abbreviated as EDG and registered under CAS number 75007-24-8. Its molecular formula is C11H17N3O8 and its molecular weight is 319.27 g/mol, placing it within the category of ultrashort peptides, well below the size of classical regulatory peptides or signaling proteins. It belongs to the group of compounds known as short peptide bioregulators or "cytogens", a family extensively characterized and studied by the research group of V. Kh. Khavinson in Saint Petersburg, which over the past decades proposed the rational design of tri- and tetrapeptides derived from tissue extracts. Within that framework, Chonluten is specifically associated with bronchopulmonary tissue and the respiratory mucosa, which is why it is usually described in that group's literature as a peptide with a "pulmonary" or "bronchial" orientation.

From a structural standpoint, Chonluten is notably simple: three amino acid residues (glutamic acid, aspartic acid, and glycine) joined by peptide bonds, with two lateral carboxyl groups contributed by the acidic residues and a glycine terminus of low steric complexity. This simplicity is central to the mechanistic hypothesis held by the Khavinson group: short peptides, because of their small size and their charge, could cross cellular and nuclear membranes and interact directly with regions of DNA or with chromatin-associated proteins, thereby modulating the transcription of certain genes. It has been proposed that these tripeptides would bind preferentially to specific sequences in the DNA groove, favoring or repressing the expression of genes linked to the differentiation and maintenance of the phenotype of the tissue of origin. It is important to emphasize that this hypothesis, although coherent and supported by in vitro and molecular modeling work by the group itself, has not been independently validated on a large scale, and the exact epigenetic mechanism remains under investigation.

In research models, Chonluten has been explored primarily in the context of respiratory tissue biology. The preclinical work published by the group that developed it describes effects on the function of bronchial and alveolar epithelial cells, on oxidative stress parameters, and on the response of lung tissue to injurious agents in animal models. It has also been studied within the general paradigm of "peptidergics" and aging, according to which the administration of these bioregulators could help restore gene expression patterns altered with age in the target tissue. For that reason it is classified within the catalog's anti-aging category, always understood as an area of research on cellular senescence and tissue homeostasis, and not as an approved therapeutic application. None of these lines should be interpreted as a clinical indication: these are observations obtained in laboratory systems, cell cultures, and animal models.

The level of evidence for Chonluten is limited and must be communicated honestly. Most of the available data comes from a single research group and from publications concentrated in a specific editorial ecosystem, without broad, independent replication by external laboratories or high-quality controlled clinical trials supporting its efficacy. There are no international regulatory approvals supporting its therapeutic use, and independent systematic reviews of the class of short peptide bioregulators tend to point to the scarcity of external data, methodological heterogeneity, and the need for better-controlled studies. Consequently, any claim of efficacy must be treated as preliminary and exploratory in nature. For the researcher, this means that Chonluten is more appropriate as a tool for studying the peptidergic hypothesis and tissue-specific gene regulation than as an agent with established properties.

With regard to its physicochemical and handling characteristics, Chonluten is usually presented in the form of a lyophilized powder. Being a peptide with two acidic residues, it shows good solubility in slightly basic or buffered aqueous media; in research protocols it is usually reconstituted in bacteriostatic water or sterile saline solution for laboratory use. As with most short peptides, it is sensitive to degradation by peptidases, so its biological half-life is presumed to be brief, a relevant factor in the design of in vivo experiments. Proper storage of the lyophilized material at low temperature and protection against light and humidity are important to preserve its integrity. Tripeptides of this type tend to be stable for prolonged periods in the dry state at -20°C, whereas reconstituted solutions have considerably lower stability and must be kept refrigerated and used within short time windows.

On a comparative level, Chonluten is part of a series of bioregulators designed by the same group, each nominally oriented toward a different tissue or organ (for example, peptides associated with thymus, liver, prostate, nervous system or cardiovascular system). It shares with them the design logic, the ultra-short size and the common mechanistic hypothesis, as well as the same evidence limitations. This membership in a coherent family is useful for contextualizing the compound, but should not be extrapolated as proof of efficacy: the results observed with one peptide of the series do not automatically transfer to the others. For research purposes, Chonluten is interesting precisely because of its declared sequence specificity and its proposed target tissue, which allows hypotheses about transcriptional regulation in the respiratory model to be studied in a targeted manner, always within a controlled experimental context and with full awareness that independent characterization of the compound is still incomplete.